In the context of therapy of the latter type of cancer, of particular interest is the ability of carbazoles to inhibit activity of tyrosinase—an enzyme that catalyzes hydroxylation of L-tyrosine to L-DOPA and its further oxidation to L-DOPA-quinone. The gene discussed is TYR; the disease is cancer.